The National Human Rights Commission today asked the All India Institute of Medical Sciences (AIIMS) to respond within four weeks to a complaint filed by an NGO against reported use of drugs meant for adults on children during clinical trials.
Falling short of issuing a notice, the NHRC forwarded the complaint registered by an NGO to the AIIMS, seeking its comments on the issue.
"The NHRC has forwarded the complaint to the AIIMS Director, besides the Secretary, Ministry of Health and asked them to send their comments within four weeks," an NHRC official said.
The NGO, whose RTI query had led to the startling disclosures about clinical trial deaths at AIIMS, sought the intervention of NHRC in the case following reports that adult drugs had been tried on babies at the premier medical institute.
In the petition submitted to NHRC, Uday Foundation invoked the violation of right to life contained in Article 21 of the constitution.
It was revealed last week that 49 children died during clinical trials of new medicines in AIIMS over the last two and a half years.
A total of 4,142 children, of whom 2,728 were under the age of one, were enrolled for the trials of new drugs and therapies by the Department of Pediatrics since January one, 2006.
Reports also suggested that children involved in clinical trials mostly belonged to the weaker sections of society.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
